Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant toripalimab plus gemcitabine and nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer
ChiCTR2100051293Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab, gemcitabine and paclitaxel in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Disease control rate. Started Sep 2021; status: recruiting.
02
Drugs
toripalimabgemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2100051293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051293.